与胰高血糖素样肽-1受体激动剂相关的胃肠道不良事件的一些风险可能由BMI解释。

IF 6.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2025-05-13 DOI:10.1111/apt.70190

Benjamin Douglas Liu,Donovan Veccia,Yan Sun,Gengqing Song

{"title":"与胰高血糖素样肽-1受体激动剂相关的胃肠道不良事件的一些风险可能由BMI解释。","authors":"Benjamin Douglas Liu,Donovan Veccia,Yan Sun,Gengqing Song","doi":"10.1111/apt.70190","DOIUrl":null,"url":null,"abstract":"We performed a re-analysis of the gastrointestinal risks of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in obese US adult patients without diabetes using the TriNetX database (GLP-1 RA n = 8792; Bupropion-naltrexone n = 8792) after accounting for initial BMI. GLP-1 RA users had higher risks of gastroparesis (aHR 2.30; 95% CI 1.19-4.46) and biliary disease (aHR 1.27; 95% CI 0.96-1.39) but did not have a conclusively elevated risk of acute pancreatitis or obstruction. Not matching for BMI suggested an elevated pancreatitis risk (aHR 1.75; 95% CI 1.13-2.70). Semaglutide conferred superior weight loss but increased biliary risk.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"96 1","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Some Risks of Gastrointestinal Adverse Events Associated With Glucagon-Like PEPTIDE-1 Receptor Agonists Are Likely Explained by BMI.\",\"authors\":\"Benjamin Douglas Liu,Donovan Veccia,Yan Sun,Gengqing Song\",\"doi\":\"10.1111/apt.70190\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We performed a re-analysis of the gastrointestinal risks of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in obese US adult patients without diabetes using the TriNetX database (GLP-1 RA n = 8792; Bupropion-naltrexone n = 8792) after accounting for initial BMI. GLP-1 RA users had higher risks of gastroparesis (aHR 2.30; 95% CI 1.19-4.46) and biliary disease (aHR 1.27; 95% CI 0.96-1.39) but did not have a conclusively elevated risk of acute pancreatitis or obstruction. Not matching for BMI suggested an elevated pancreatitis risk (aHR 1.75; 95% CI 1.13-2.70). Semaglutide conferred superior weight loss but increased biliary risk.\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\"96 1\",\"pages\":\"\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2025-05-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/apt.70190\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.70190","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们使用TriNetX数据库(GLP-1 RA n = 8792；安非他酮-纳曲酮n = 8792)。GLP-1 RA使用者胃轻瘫的风险更高(aHR 2.30；95% CI 1.19-4.46)和胆道疾病(aHR 1.27；95% CI 0.96-1.39)，但急性胰腺炎或梗阻的风险没有明显升高。BMI不匹配提示胰腺炎风险升高(aHR 1.75；95% ci 1.13-2.70)。西马鲁肽减轻了体重，但增加了胆道风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon-Like PEPTIDE-1 Receptor Agonists Are Likely Explained by BMI.

We performed a re-analysis of the gastrointestinal risks of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in obese US adult patients without diabetes using the TriNetX database (GLP-1 RA n = 8792; Bupropion-naltrexone n = 8792) after accounting for initial BMI. GLP-1 RA users had higher risks of gastroparesis (aHR 2.30; 95% CI 1.19-4.46) and biliary disease (aHR 1.27; 95% CI 0.96-1.39) but did not have a conclusively elevated risk of acute pancreatitis or obstruction. Not matching for BMI suggested an elevated pancreatitis risk (aHR 1.75; 95% CI 1.13-2.70). Semaglutide conferred superior weight loss but increased biliary risk.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.